Nir Barzilai

Last updated
Nir Barzilai
Born(1955-12-27)December 27, 1955
Haifa, Israel
CitizenshipUnited States of America and Israel
Alma materTechnion-Israel Institute of Technology
Known forbiology of aging, genetics of exceptional longevity
AwardsIrving S. Wright Award of Distinction in Aging Research Award (September 2010)
Scientific career
Fieldsgenetics and biology of aging, endocrinology/diabetes
InstitutionsAlbert Einstein College of Medicine

Nir Barzilai (born December 27, 1955) is an Israeli geneticist and longevity researcher.

Contents

Biography

Barzilai is the founding director of the Institute for Aging Research, [1] the Nathan Shock Center of Excellence in the Basic Biology of Aging and the Paul F. Glenn Center for the Biology of Human Aging Research at Albert Einstein College of Medicine (Einstein). He also directs the Longevity Genes Project, [2] a genetics study of over 600 families of centenarians and their children. The participants are all Ashkenazi Jews, a group selected for their genetic homogeneity, which makes it easier to identify significant genetic variations. Barzilai found that many of the centenarians had very high levels of HDL. [3] Barzilai also co-founded of CohBar, Inc., a biotechnology company developing mitochondria based therapeutics to treat diseases associated with aging.

Barzilai discovered several “longevity genes” in humans that were validated by others. [4] These include variants in genes involved in cholesterol metabolism (CETP [5] and APOC3 [6] ), metabolism (ADIPOQ [7] and TSHR [8] ) and growth (IGF1R [9] ). These genes appear to protect centenarians against major age-related diseases, such as cardiovascular disease, cancer, type 2 diabetes and dementia. [10]

Treatments for age-related diseases were under development based on Barzilai’s work. A collaboration with Merck conducted early-stage clinical trials but ultimately abandoned Anacetrapib. The diabetes research is led by CohBar Inc., [11] a biotech company that Barzilai helped co-found.

In addition to his “longevity gene” research, Barzilai studies key mechanisms involved in the biology of aging, including how nutrients [12] and genetics [13] influence lifespan. He has also proposed metformin as a tool to target aging [14] and has run the Metformin in Longevity Study (completed May 2018) [15] He is also investigating how mental decline and personality affect longevity. [16]

Barzilai was born in Haifa, Israel. During his national service in the Israel Defense Forces, he served as a medical instructor. In 1976, he served as a medical officer in Operation Entebbe. He was the Israeli army's chief medic from 1977 to 1985. He studied medicine at the Technion – Israel Institute of Technology, obtaining his MD in 1985. He interned at Rambam Medical Center in Haifa, Hadassah Medical Center in Jerusalem, and the Royal Free Hospital in London. He first came to the U.S. in 1987 as a resident at Yale University. He joined Einstein in 1993 as an instructor of medicine (endocrinology). [17] [18]

Selected publications

Related Research Articles

<span class="mw-page-title-main">Penetrance</span> Proportion of individuals that express the trait associated with a gene variant

Penetrance in genetics is the proportion of individuals carrying a particular variant of a gene (genotype) that also expresses an associated trait (phenotype). In medical genetics, the penetrance of a disease-causing mutation is the proportion of individuals with the mutation that exhibit clinical symptoms among all individuals with such mutation. For example: If a mutation in the gene responsible for a particular autosomal dominant disorder has 75% penetrance, then 75% of those with the mutation will go on to develop the disease, showing its phenotype, whereas 25% will not. 

Life extension is the concept of extending the human lifespan, either modestly through improvements in medicine or dramatically by increasing the maximum lifespan beyond its generally-settled biological limit of around 125 years. Several researchers in the area, along with "life extensionists", "immortalists", or "longevists", postulate that future breakthroughs in tissue rejuvenation, stem cells, regenerative medicine, molecular repair, gene therapy, pharmaceuticals, and organ replacement will eventually enable humans to have indefinite lifespans through complete rejuvenation to a healthy youthful condition (agerasia). The ethical ramifications, if life extension becomes a possibility, are debated by bioethicists.

<span class="mw-page-title-main">Longevity</span> Longer than typical lifespan, especially of humans

Longevity may refer to especially long-lived members of a population, whereas life expectancy is defined statistically as the average number of years remaining at a given age. For example, a population's life expectancy at birth is the same as the average age at death for all people born in the same year.

<span class="mw-page-title-main">Metformin</span> Medication used to treat diabetes by reducing glucose levels

Metformin, sold under the brand name Glucophage, among others, is the main first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight. It is also used in the treatment of polycystic ovary syndrome. It is sometimes used as an off-label adjunct to lessen the risk of metabolic syndrome in people who take antipsychotics. Metformin is not associated with weight gain and is taken by mouth.

<span class="mw-page-title-main">Pharmacogenomics</span> Study of the role of the genome in drug response

Pharmacogenomics, often abbreviated "PGx," is the study of the role of the genome in drug response. Its name reflects its combining of pharmacology and genomics. Pharmacogenomics analyzes how the genetic makeup of a patient affects their response to drugs. It deals with the influence of acquired and inherited genetic variation on drug response, by correlating DNA mutations with pharmacokinetic, pharmacodynamic, and/or immunogenic endpoints.

<span class="mw-page-title-main">Cholesteryl ester transfer protein</span> Mammalian protein found in Homo sapiens

Cholesteryl ester transfer protein (CETP), also called plasma lipid transfer protein, is a plasma protein that facilitates the transport of cholesteryl esters and triglycerides between the lipoproteins. It collects triglycerides from very-low-density (VLDL) or Chylomicrons and exchanges them for cholesteryl esters from high-density lipoproteins (HDL), and vice versa. Most of the time, however, CETP does a heteroexchange, trading a triglyceride for a cholesteryl ester or a cholesteryl ester for a triglyceride.

<span class="mw-page-title-main">Apolipoprotein E</span> Cholesterol-transporting protein most notably implicated in Alzheimers disease

Apolipoprotein E (Apo-E) is a protein involved in the metabolism of fats in the body of mammals. A subtype is implicated in Alzheimer's disease and cardiovascular diseases. It is encoded in humans by the gene APOE.

<span class="mw-page-title-main">Battenin</span> Protein-coding gene in the species Homo sapiens

Battenin is a protein that in humans is encoded by the CLN3 gene located on chromosome 16. Battenin is not clustered into any Pfam clan, but it is included in the TCDB suggesting that it is a transporter. In humans, it belongs to the atypical SLCs due to its structural and phylogenetic similarity to other SLC transporters.

<span class="mw-page-title-main">Fumarylacetoacetate hydrolase</span>

Fumarylacetoacetase is an enzyme that in humans is encoded by the FAH gene located on chromosome 15. The FAH gene is thought to be involved in the catabolism of the amino acid phenylalanine in humans.

<span class="mw-page-title-main">Genome-wide association study</span> Study of genetic variants in different individuals

In genomics, a genome-wide association study, is an observational study of a genome-wide set of genetic variants in different individuals to see if any variant is associated with a trait. GWA studies typically focus on associations between single-nucleotide polymorphisms (SNPs) and traits like major human diseases, but can equally be applied to any other genetic variants and any other organisms.

<span class="mw-page-title-main">FOXO3</span> Protein-coding gene in the species Homo sapiens

Forkhead box O3, also known as FOXO3 or FOXO3a, is a human protein encoded by the FOXO3 gene.

<span class="mw-page-title-main">Sirtuin 1</span> Protein

Sirtuin 1, also known as NAD-dependent deacetylase sirtuin-1, is a protein that in humans is encoded by the SIRT1 gene.

Paola Sebastiani is a biostatistician and a professor at Boston University working in the field of genetic epidemiology, building prognostic models that can be used for the dissection of complex traits. Her research interests include Bayesian modeling of biomedical data, particularly genetic and genomic data.

A centenarian is a person who has attained the age of 100 years or more. Research on centenarians has become more common with clinical and general population studies now having been conducted in France, Hungary, Japan, Italy, Finland, Denmark, the United States, and China. Centenarians are the second fastest-growing demographic in much of the developed world. By 2030, it is expected that there will be around a million centenarians worldwide. In the United States, a 2010 Census Bureau report found that more than 80 percent of centenarians are women.

The medical genetics of Jews have been studied to identify and prevent some rare genetic diseases that, while still rare, are more common than average among people of Jewish descent. There are several autosomal recessive genetic disorders that are more common than average in ethnically Jewish populations, particularly Ashkenazi Jews, because of relatively recent population bottlenecks and because of consanguineous marriage. These two phenomena reduce genetic diversity and raise the chance that two parents will carry a mutation in the same gene and pass on both mutations to a child.

<span class="mw-page-title-main">ACAA2</span> Gene

3-Ketoacyl-CoA thiolase, mitochondrial also known as acetyl-Coenzyme A acyltransferase 2 is an enzyme that in humans is encoded by the ACAA2 gene.

Jan Vijg is the Lola and Saul Kramer Chairperson in Molecular Genetics at the Department of Genetics at the Albert Einstein College of Medicine, New York City, United States. Prior to this appointment, he was a professor at the Buck Institute for Research on Aging.

<span class="mw-page-title-main">FOXO6</span> Protein-coding gene in the species Homo sapiens

Forkhead box O6 is a protein that in humans is encoded by the FOXO6 gene.

This timeline lists notable events in the history of research into senescence or biological aging, including the research and development of life extension methods, brain aging delay methods and rejuvenation.

<span class="mw-page-title-main">Katalin Susztak</span> Hungarian-American nephrologist

Katalin Susztak (Suszták) is a Hungarian American scientist and nephrologist at the Perelman School of Medicine at the University of Pennsylvania. She is a professor of medicine and genetics, and currently the codirector of the Complications Unit at the Institute for Diabetes, Obesity and Metabolism. Her laboratory made major contributions to the current understanding of kidney disease development. She is also the founder of the Transformative Research In DiabEtic NephropaThy (TRIDENT), a collaborative network of physicians and basic scientists, to find cures for diabetic kidney disease.

References

  1. ↑ "Institute for Aging Research". Albert Einstein College of Medicine. Archived from the original on October 29, 2010. Retrieved April 29, 2014.
  2. ↑ Dreifus, Claudia (February 24, 2004). "A CONVERSATION WITH/Nir Barzilai; It's Not the Yogurt: Looking for Longevity Genes". New York Times. New York, NY. Retrieved April 29, 2014.
  3. ↑ deGrasse Tyson, Neil (host); Cohen, Chad (correspondent) (Jan 2007). "Aging". NOVA scienceNOW. PBS.
  4. ↑ Green, Jesse (November 6, 2011). "What Do a Bunch of Old Jews Know About Living Forever?". New York (magazine). NY, NY. Retrieved April 30, 2013.
  5. ↑ Barzilai, N; Atzmon, G; Schechter, C; Schaefer, EJ; Cupples, AL; Lipton, R; Cheng, S; Shuldiner, AR (October 15, 2003). "Unique lipoprotein phenotype and genotype associated with exceptional longevity". JAMA. 290 (15): 2030–2040. doi:10.1001/jama.290.15.2030. PMID   14559957.
  6. ↑ Atzmon, G; Rincon, M; Schechter, C; Shuldiner, An; Lipton, R; Bergman, A; Barzilai, N (April 4, 2006). "Lipoprotein Genotype and Conserved Pathway for Exceptional Longevity in Humans". PLOS Biol. 4 (4): e113. doi: 10.1371/journal.pbio.0040113 . PMC   1413567 . PMID   16602826. Open Access logo PLoS transparent.svg
  7. ↑ Atzmon, G; Polin, TI; Crandall, J; Tanner, K; Schechter, CB; Scherer, PE; Rincon, M; Siegel, G; Katz, M; Lipton, RB; Shuldiner, AR; Barzilai, N (2008). "Adiponectin levels and genotype: A potential regulator of life-span in humans". Journal of Gerontology: Biological Sciences. 63 (5): 447–453. doi:10.1093/gerona/63.5.447. PMC   4507412 . PMID   18511746.
  8. ↑ Atzmon, G; Barzilai, N; Hollowell, JG; Surks, MI; Gabriely, I (October 16, 2009). "Genetic Predisposition to Elevated Serum Thyrotropin is Associated with Exceptional Longevity". The Journal of Clinical Endocrinology & Metabolism. 94 (12): 4768–4775. doi:10.1210/jc.2009-0808. PMC   2795660 . PMID   19837933.
  9. ↑ Suh, Y; Atzmon, G; Cho, M-O; Hwang, D; Liu, B; Leahy, D; Barzilai, N; Cohen, P (March 4, 2008). "Functionally-significant insulin-like growth factor-I receptor mutations in centenarian". PNAS. 105 (9): 3438–3442. Bibcode:2008PNAS..105.3438S. doi: 10.1073/pnas.0705467105 . PMC   2265137 . PMID   18316725.
  10. ↑ Carey, Benedict (May 21, 2009). "At the Bridge Table, Clues to a Lucid Old Age". The New York Times. Retrieved April 30, 2014.
  11. ↑ P. Cohen Eureka Grant (2013-03-06). "CohBar, Inc: Innovations in the Treatment of Age-Related Diseases". Cohbar.com. Retrieved 2014-04-24.
  12. ↑ Barzilai, N; Huffman, DM; Muzumdar, RH; Bartke, A (June 2012). "The critical role of metabolic pathways in aging". Diabetes. 61 (6): 1315–1322. doi:10.2337/db11-1300. PMC   3357299 . PMID   22618766 . Retrieved April 30, 2014.
  13. ↑ Barzilai, N; Guarente, L; Kirkwood, TB; Patridge, L; Rando, TA; Slagboom, PE (July 10, 2012). "The place of genetics in ageing research". Nature Reviews Genetics. 13 (8): 589–594. doi:10.1038/nrg3290. PMID   22777128. S2CID   23717998.
  14. ↑ Barzilai, Nir; Crandall, Jill P.; Kritchevsky, Stephen B.; Espeland, Mark A. (2016-06-14). "Metformin as a Tool to Target Aging". Cell Metabolism. 23 (6): 1060–1065. doi:10.1016/j.cmet.2016.05.011. ISSN   1550-4131. PMC   5943638 . PMID   27304507.
  15. ↑ Kulkarni AS, Brutsaert EF, Anghel V, Zhang K, Bloomgarden N, Pollak M, et al. (2018). "Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults". Aging Cell. 17 (2): e12723. doi:10.1111/acel.12723. PMC   5847877 . PMID   29383869.
  16. ↑ Kato, K; Zweig, R; Schechter, C; Verghese, J; Barzilai, N; Atzmon, G (March 23, 2013). "Personality, self-rated health, and cognition in centenarians: Do personality and self-rated health relate to cognitive function in advanced age?". Aging. 5 (3): 183–191. doi:10.18632/aging.100545. PMC   3629290 . PMID   23524310.
  17. ↑ "Nir Barzilai CV" (PDF). Albert Einstein College of Medicine. Mar 31, 2012. Retrieved April 30, 2014.
  18. ↑ USA: Nir Barzilai (Technion, Hadassah), the man who wants to beat back aging
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.